• Loading stock data…

Rallybio Announces Clinical Proof of Concept for RLYB211, an Anti-HPA-1a Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

[#item_full_content]

Print Friendly, PDF & Email
Spread the word